Announcements Trials
Browse Landscape

Phase

Phase 1 5Phase NA 4Phase 2 3Phase 3 1Phase 1/2 1

Status

Recruiting 19Active not recruiting 9Completed 7Withdrawn 5Suspended 3Not yet recruiting 3Unknown 1Terminated 1

Sponsor Class

OTHER 2NIH 1NETWORK 1INDUSTRY 1

Study Type

Interventional 5

Sponsor

Cancer Type

Lymphoid 2Other hematologic neoplasm 1Genitourinary 1Breast 1

Conditions

Triple Negative Breast Neoplasms 1Prostatic Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Opioid-Related Disorders 1Lymphoma, Follicular 1Leukemia, Myeloid, Acute 1Leukemia, Biphenotypic, Acute 1Advanced Cancers 1

Interventions

Cyclophosphamide 35Cisplatin 24fludarabine 23Radiotherapy 23Paclitaxel 21Carboplatin 20pembrolizumab 18Nivolumab 18Magnetic Resonance Spectroscopy 18Specimen Handling 17fludarabine phosphate 15Gemcitabine 15Biopsy 15Cytarabine 14Radiation 11Filgrastim 11Doxorubicin 11Docetaxel 11Dexamethasone 11Radiosurgery 10Granulocyte Colony-Stimulating Factor 10Etoposide 10Melphalan 9Ipilimumab 9venetoclax 8Rituximab 8Calcium Dobesilate 8trametinib 7ibrutinib 7durvalumab 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 1 × Withdrawn × X-Rays × Clear all
NCT07498465 2026-05-05

A Study to Find the Highest Dose of SNDX-5613 (Revumenib) as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, and Mixed Phenotype Acute Leukemia

Children's Oncology Group

Phase 1 Withdrawn
LymphoidOther hematologic neoplasm

Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT06590558 2025-07-03

Testing the Addition of an Investigational Anti-Cancer Drug, ASTX660 (Tolinapant), to a Usual Chemotherapy Treatment (Eribulin) for Treatment of Advanced Triple Negative Breast Cancer

National Cancer Institute (NCI)

Phase 1 Withdrawn
Breast

Triple Negative Breast Neoplasms

NCT06094842 2025-04-01

Autologous T Cells Lentivirally Transduced to Express L1CAM-Specific Chimeric Antigen Receptors in Treating Patients With Locally Advanced and Unresectable or Metastatic Small Cell Neuroendocrine Prostate Cancer

Fred Hutchinson Cancer Center

Phase 1 Withdrawn
Genitourinary

Prostatic Neoplasms

NCT05251376 2023-01-19

Study of LYN-014 in Individuals With Opioid Use Disorder Who Are Stable on Methadone Therapy

Lyndra Inc.

Phase 1 Withdrawn
Lymphoid

Lymphoma, Follicular, Opioid-Related Disorders

NCT01432119 2013-04-09

Phase 1 Trial With SIR-Spheres and Cetuximab +/- Erlotinib

M.D. Anderson Cancer Center

Phase 1 Withdrawn

Advanced Cancers

Data powered by HemOnc (CC BY 4.0) Colophon âš¡